Journal of Addiction Medicine最新文献

{"title":"Racial and Ethnic Disparities in Referral Rejection From Postacute Care Facilities Among People With Opioid Use Disorder in Massachusetts.","authors":"Sophie Rosenmoss, Marc LaRochelle, Benjamin Bearnot, Zoe Weinstein, Kaku So-Armah, Patience Moyo, Shapei Yan, Alexander Y Walley, Simeon D Kimmel","doi":"10.1097/ADM.0000000000001390","DOIUrl":"10.1097/ADM.0000000000001390","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of the study was to examine the association between Black, White, and Hispanic or Latino race and ethnicity and referral rejection from private postacute care facilities among hospitalized individuals with opioid use disorder (OUD).</p><p><strong>Methods: </strong>In this retrospective cohort study, we linked electronic postacute care referrals from Boston Medical Center in 2018 to electronic medical record data, which we used to ascertain OUD status and race and ethnicity. Using multivariable logistic regression, we examined the association between Black, White, and Hispanic or Latino race and ethnicity and referral rejection, adjusting for individual-level characteristics including medication for opioid use disorder treatment type and for facility-level factors using facility random effects.</p><p><strong>Results: </strong>We identified 159 hospitalizations from 141 individuals with OUD referred to private postacute medical care, corresponding to 1272 referrals to 244 facilities. Hospitalizations comprised 53 (33%) non-Hispanic Black, 28 (18%) Hispanic or Latino, and 78 (49%) non-Hispanic White individuals. In adjusted analyses, referrals for non-Hispanic Black individuals had significantly higher odds of rejection compared to referrals for non-Hispanic White individuals (adjusted odds ratio 1.83, 95% confidence interval [1.24, 2.69], P = 0.002). There were no significant differences between referrals for Hispanic or Latino individuals and non-Hispanic White individuals (adjusted odds ratio 1.11, 95% confidence interval [0.67, 1.84], P = 0.69).</p><p><strong>Conclusions: </strong>Among people with OUD referred to private postacute care in Massachusetts, non-Hispanic Black individuals were more likely to be rejected compared to non-Hispanic White individuals, demonstrating racism in postacute care admissions. Efforts to address discrimination against people with OUD in postacute care admissions must also address racial equity.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"165-171"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Participation in Prenatal Substance Use Assessment, Counseling, and Treatment Among Pregnant Individuals in Prenatal Settings Who Use Cannabis.","authors":"Gwen T Lapham, Felicia W Chi, Kelly C Young-Wolff, Deborah Ansley, Carley Castellanos, Monique B Does, Asma H Asyyed, Allison Ettenger, Cynthia I Campbell","doi":"10.1097/ADM.0000000000001399","DOIUrl":"10.1097/ADM.0000000000001399","url":null,"abstract":"<p><strong>Objectives: </strong>Assessment and counseling are recommended for individuals with prenatal cannabis use. We examined characteristics that predict prenatal substance use assessment and counseling among individuals who screened positive for prenatal cannabis use in prenatal settings.</p><p><strong>Methods: </strong>Electronic health record data from Kaiser Permanente Northern California's Early Start perinatal substance use screening, assessment, and counseling program was used to identify individuals with ≥1 pregnancies positive for prenatal cannabis use. Outcomes included completion of a substance use assessment and among those assessed, attendance in Early Start counseling only or Addiction Medicine Recovery Services (AMRS) treatment. Predictors included demographics and past-year psychiatric and substance use disorder diagnoses evaluated with GEE multinomial logistic regression.</p><p><strong>Results: </strong>The sample included 17,782 individuals with 20,398 pregnancies positive for cannabis use (1/2011-12/2021). Most pregnancies (80.3%) had an assessment. Individuals with Medicaid, anxiety, depression and tobacco use disorders, compared to those without, had higher odds and those with greater parity, older age (≥35) and in later trimesters, had lower odds of assessment. Among 64% (n = 10,469) pregnancies needing intervention based on assessment, most (88%) attended Early Start counseling only or AMRS (with or without Early Start). Greater parity and later trimester assessment was associated with lower odds, while Medicaid was associated with higher odds of Early Start counseling. Nearly all diagnosed psychiatric and substance use disorders were associated with higher odds of AMRS treatment.</p><p><strong>Conclusions: </strong>A comprehensive prenatal substance use program engaged most pregnant individuals with prenatal cannabis use in substance use assessment and counseling. Opportunities to improve care gaps remain.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"179-186"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11895816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142962251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"5-Day Injectable Extended-release Buprenorphine Initiation in Non-opioid-tolerant Individuals in a Carceral Setting: A Case Series.","authors":"Matt Perdue, Reza Hosseini Ghomi, Paul Rees, Eric Arzubi","doi":"10.1097/ADM.0000000000001387","DOIUrl":"10.1097/ADM.0000000000001387","url":null,"abstract":"<p><strong>Background: </strong>Injectable extended-release buprenorphine (XR-Bup) addresses several barriers to the implementation of treatment with medications for opioid use disorder (MOUD) in carceral settings due to lower risk of diversion and reduced operational procedures. However, there is no standardized approach or guideline for initiating sublingual buprenorphine (SL-Bup) and transitioning to XR-Bup in persons with opioid use disorder (OUD) who are not actively using opioids, a clinical scenario commonly encountered in carceral settings.</p><p><strong>Methods: </strong>We conducted a retrospective case series of non-opioid-tolerant men with OUD at a Montana Department of Corrections facility who initiated XR-Bup using a 5-day induction protocol between May 1, 2023, and November 1, 2023. Primary outcome was receipt of the initial XR-Bup injection. Secondary outcomes were toleration of SL-Bup induction protocol and active continuation of XR-Bup at time of discharge.</p><p><strong>Results: </strong>Sixteen individuals initiated the SL-Bup induction protocol, and all were successfully transitioned to XR-Bup with no severe adverse effects. There were no required dose changes or severe adverse effects from SL-Bup induction. Two (12%) elected to discontinue XR-Bup due to commonly reported adverse effects. Fourteen (88%) remained on XR-Bup at discharge.</p><p><strong>Conclusions: </strong>Five-day induction of SL-Bup and transition to XR-Bup may be considered for non-opioid-tolerant individuals with OUD in carceral settings.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"227-229"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: \"Chronic Pain Associated Alcohol Use Disorder Among Participants in a Small Clinical Trial\".","authors":"Nicholas J Bush, Erin Ferguson, Emily Zale, Jeff Boissoneault","doi":"10.1097/ADM.0000000000001394","DOIUrl":"10.1097/ADM.0000000000001394","url":null,"abstract":"","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"238"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Buprenorphine, Methadone, and Substance Use on COVID-19 Morbidity and Mortality.","authors":"Nicholaus J Christian, Xin Zhou, Rajiv Radhakrishnan","doi":"10.1097/ADM.0000000000001386","DOIUrl":"10.1097/ADM.0000000000001386","url":null,"abstract":"<p><strong>Objectives: </strong>Substance use disorder has been associated with increased morbidity in COVID-19 infection. However, less is known about the impact of active substance use and medications for opioid use disorder (MOUD) on COVID-19 outcomes. We conducted a retrospective cohort study to evaluate the impact of substance use, namely, cannabis, cocaine, alcohol, sedative and opioid use; and buprenorphine or methadone on COVID-19 morbidity and mortality.</p><p><strong>Methods: </strong>Using electronic health record data at a large urban hospital system, patients who tested positive for COVID-19 between January 1, 2020, and December 31, 2021, were included. Substance use was identified from urine toxicology and MOUD prescriptions within 90 days prior to admission. COVID-19 outcomes included mortality, ICU admission, need for intubation, and number and duration of hospitalizations. Multivariable logistic regression was performed controlling for variables such as age, sex, medical comorbidity, tobacco use, and social disadvantage.</p><p><strong>Results: </strong>Among COVID-19-positive patients (n = 17,423), sedative, cannabis, cocaine, and opioid use was associated with statistically significant increases in need for ICU care, need for ventilatory support, number of hospitalizations, and duration of hospitalization. Substance use was not associated with an increase in all-cause mortality. There were no statistically significant differences between methadone, buprenorphine, and other opioids on COVID-19 outcomes.</p><p><strong>Conclusions: </strong>Active substance use was associated with increased morbidity in COVID-19 infection. MOUD was not associated with worse COVID-19 outcomes compared to other opioids. Future studies focused on MOUD treatments that reduce morbidity may help improve clinical outcomes in COVID-19.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"223-226"},"PeriodicalIF":4.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Buprenorphine Adherence Trajectories, Health Outcomes, and Health Care Costs Among Medicaid Enrollees.","authors":"Olajumoke A Olateju, Chijioke Okeke, Mina Shrestha, Douglas Thornton","doi":"10.1097/ADM.0000000000001458","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001458","url":null,"abstract":"<p><strong>Objectives: </strong>To identify distinct buprenorphine adherence trajectories among patients with opioid use disorder (OUD) and evaluate their associations with health events and health care costs.</p><p><strong>Methods: </strong>A retrospective longitudinal cohort study was conducted using the Merative Multi-state Medicaid database. The study analyzed 12,244 Medicaid enrollees aged 18-64 years who were diagnosed with OUD and initiated buprenorphine treatment between July 1, 2017 and June 30, 2019. Group-based trajectory models were used to identify adherence patterns during the first 180 days of treatment. Cox proportional hazard models were used to evaluate the associations between adherence trajectories and time to opioid overdose, substance use disorder-related hospitalization, and all-cause hospitalization. Generalized linear models were used to compare health care costs across trajectories.</p><p><strong>Results: </strong>Four buprenorphine adherence trajectories were identified: completely adherent (50.8%), initially adherent with later decline (13.6%), increasing adherence with later decline (9.9%), and continuously declining nonadherence (25.8%). Compared to the completely adherent group, patients in other groups had a higher risk of opioid overdose, hospitalization and increased health care costs. The continuously declining nonadherent group demonstrated the highest risks, with an opioid overdose hazard ratio (HR) of 1.92 (95% CI, 1.46-2.39), all-cause hospitalization of HR of 1.71 (95% CI: 1.58-1.85), and substance use disorder (SUD)-related hospitalization HR of 2.01 (95% CI: 1.82-2.15). Additionally, healthcare costs were notably higher compared to the completely adherent group, with an increase of $1482.45 (95% CI: $745.45-$2756.01) in the increasing adherence with later decline group and $1698.46 (95% CI: $432.57-$3087.78) in the continuously declining nonadherence groups.</p><p><strong>Conclusions: </strong>Almost half of Medicaid beneficiaries with OUD exhibited varying degrees of nonadherence to buprenorphine within 180 days of treatment initiation. This nonadherence was associated with adverse clinical outcomes and increased health care costs. Health care providers should consider adherence challenges when designing therapeutic interventions with buprenorphine.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Privacy, Care-seeking, and Stigma: A Qualitative Investigation of Patient Perspectives on Sharing Substance Use Disorder Treatment Records.","authors":"James Aluri, Evelyn Gurule, Tulha Dobler Siddiqi, Camryn R Upson, Adam D'Sa, Eric C Strain, Denis G Antoine","doi":"10.1097/ADM.0000000000001460","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001460","url":null,"abstract":"<p><strong>Objectives: </strong>To examine, among persons with substance use disorders (SUDs), how their decision-making to seek care is influenced by concerns about the privacy of their treatment records, how they weigh the risks and benefits of record sharing, and their awareness of how records are shared and regulated.</p><p><strong>Methods: </strong>This qualitative study followed the Standards for Reporting Qualitative Research and analyzed semi-structured interviews of 13 men and 14 women recruited from inpatient and residential SUD treatment programs. Due to the onset of the COVID-19 pandemic, recruitment took place over an extended period (between May 2020 and July 2023). Interview transcripts were analyzed using qualitative thematic analysis. Saturation was checked using established quantitative methods.</p><p><strong>Results: </strong>Most participants reported that privacy concerns about their records were not a significant factor in the decision to seek treatment. Participants identified many benefits to record sharing, and stigma was viewed as a primary risk. Several women reported that health care professionals, particularly in emergency or perinatal care contexts, treated them differently or negatively after learning about their substance use history. Most participants were unaware of how their substance use treatment records were protected or who had access to their records.</p><p><strong>Conclusions: </strong>Sharing of SUD treatment records with health care professionals was generally viewed positively and privacy concerns did not appear to deter participants from seeking care. Stigma was a concern among participants, especially women. The unawareness of how records are shared highlights the need to better engage persons with SUDs in clinical conversations about their records.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individuals Dispensed Buprenorphine in the United States Before and After Federal Policy Changes Aimed at Increasing Access.","authors":"Gery P Guy, Christopher M Jones, Michaela Rikard, Andrea E Strahan, Kun Zhang, Yngvild Olsen","doi":"10.1097/ADM.0000000000001457","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001457","url":null,"abstract":"<p><strong>Objectives: </strong>Buprenorphine can decrease opioid use disorder and mortality risk but remains underutilized. This study evaluates changes in monthly buprenorphine dispensing associated with federal policy changes in the United States from 2018 to 2023.</p><p><strong>Methods: </strong>This study used interrupted time series analysis comparing the monthly rate of patients dispensed buprenorphine after the implementation of telehealth flexibilities in March 2020, relaxation of training requirements in April 2021, and removal of waiver requirements in December 2022. Buprenorphine formulated for opioid use disorder was included from the IQVIA Total Patient Tracker.</p><p><strong>Results: </strong>Before March 2020, the monthly rate of individuals dispensed buprenorphine was increasing. The rate of increase slowed after each policy change: -0.69 (95% CI=-1.00 to -0.39) after telehealth flexibilities were initiated, -0.60 (95% CI=-0.92 to -0.27) after relaxing training requirements, and -0.49 (95% CI=-0.73 to -0.24) after waiver elimination. After the elimination of the waiver, declines were observed across several specialty groups, including pain medicine, emergency medicine, and primary care, while the rate increased among addiction medicine specialists.</p><p><strong>Conclusions: </strong>After each policy change, the rate of individuals dispensed buprenorphine increased at a slower rate than before each policy change. These findings suggest that the removal of the waiver, while important, may not be sufficient on its own to meaningfully expand buprenorphine prescribing. Individual and systems-level strategies may be needed to fully optimize the impact of these policy changes focusing on reducing patient, clinician, and institutional stigma, addressing clinician barriers, implementing systems-level improvements, and strengthening payment policies that incentivize prescribing.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outpatient Alcohol Withdrawal Management in a Substance Use Disorder Bridge Clinic: An Opportunity for Low-barrier Engagement and Shared Decision-making.","authors":"Alyssa F Peterkin, Jordana Laks, Natalija Farrell, Karrin Weisenthal, Jessica L Taylor","doi":"10.1097/ADM.0000000000001463","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001463","url":null,"abstract":"<p><strong>Objective: </strong>To describe the implementation of outpatient alcohol withdrawal management in a low-barrier substance use disorder (SUD) bridge clinic and short-term clinical outcomes.</p><p><strong>Methods: </strong>A bridge clinic in Boston, MA implemented outpatient benzodiazepine tapers for alcohol withdrawal in patients at low risk of alcohol withdrawal seizures or delirium tremens. We conducted a retrospective chart review of patients who received one or more benzodiazepine doses between April 2021 and January 2023. We described patient characteristics and evaluated rates of taper completion, clinical complications, and medication for alcohol use disorder (AUD) initiation.</p><p><strong>Results: </strong>Forty-six patients with alcohol withdrawal were treated during the study period. Their mean age was 43 years and the majority identified as male (76%); ∼30% were Black/African American and 30% Hispanic/Latinx, and 24% spoke a primary language other than English. Most had severe AUD (76%), and 30% had a history of complicated withdrawal, counter to typical clinical eligibility criteria. Over a third of patients (19/46, 41.6%) completed their planned withdrawal treatment course, 18 (39.1%) patients did not follow up in the bridge clinic within the first 3 days, and 1 (2%) experienced a documented seizure during treatment. Twenty-four patients (52%) initiated medication for AUD.</p><p><strong>Conclusion: </strong>Outpatient alcohol withdrawal management in a bridge clinic provides an opportunity to engage patients from marginalized groups, including those at higher risk for complicated alcohol withdrawal who decline inpatient care. More work is needed to improve patient follow-up and assess treatment outcomes.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Menstrual Pain and Substance Use in Women Receiving Inpatient Treatment for Substance Use Disorders.","authors":"Dawn E Sugarman, Mia A Haidamus, R Kathryn McHugh, Margaret L Griffin, Roger D Weiss, Laura A Payne","doi":"10.1097/ADM.0000000000001468","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001468","url":null,"abstract":"<p><strong>Objectives: </strong>Pain is a risk factor for substance use and can negatively affect outcomes of substance use disorder (SUD) treatment. Menstrual pain is common among menstruating women yet has received little attention in the substance use literature. This study aimed to characterize menstrual pain and explore the association between menstrual pain and substance use in women receiving SUD treatment.</p><p><strong>Methods: </strong>Participants in SUD inpatient treatment were recruited for a cross-sectional self-report survey study. The current analyses focused on participants who reported a menstrual cycle in the past 6 months (N=56) and completed a questionnaire to assess menstrual cycle characteristics, menstrual pain severity, and menstrual pain interference. Substance use (eg, alcohol, cocaine) and misuse of medications to relieve menstrual pain (ie, used without a prescription or in any way other than prescribed) was also assessed.</p><p><strong>Results: </strong>Half of the participants (n=28) reported using substances for menstrual pain; the most commonly used substances were cannabis, alcohol, and nicotine/tobacco. Menstrual pain severity was associated with substance use to manage menstrual pain (B=0.34, SEB=0.11, P<0.01); higher pain interference was associated with higher odds of using substances to manage menstrual pain (B=0.55, SEB=0.16, P<0.001).</p><p><strong>Conclusions: </strong>These results indicate that menstrual pain is highly prevalent in this population and may be a risk factor for substance use among women in SUD treatment. Conducting menstrual history assessments with patients seeking SUD treatment might be clinically helpful. It may also be helpful for clinicians to closely monitor the impact of menstrual pain on substance use and treatment outcomes.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}